Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the prevalence of obesity has reached epidemic proportion in the seven major markets included in this report (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and is expected to continue growing. As a result of the increasing prevalence and the availability of new drug options, the drug-treated population will grow 7.4% annually, from 2.3 million in 2005 to 4.7 million in 2015.

According to a new Pharmacor report entitled Obesity, sales of obesity agents will increase fivefold between 2005 and 2015. Rising prevalence of obesity, increasing recognition of obesity as a disease, and the launch of Sanofi-Aventis's Acomplia will all combine to significantly grow the market.

The report also finds that the lack of reimbursement for obesity drugs will continue to inhibit consumer uptake, particularly among low-income patients, who often exhibit high rates of obesity.

"As long as obesity is viewed as a lifestyle issue rather than a disease, healthcare systems are unlikely to reimburse antiobesity drugs," said Amy Walker, analyst at Decision Resources. "However, physicians interviewed assure us that this perception is changing, giving hope for future reimbursement."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

New Oral Agents for Multiple Sclerosis, Including Novartis/Mitsubishi Pharma's Novel Drug, Will Capture 25% of Market Share by 2020

View Now